Park Avenue

Prevent Blindness Names Ed Buffington, GPN Technologies, as the 2024 Person of Vision Award Recipient

Retrieved on: 
Thursday, September 28, 2023
Emerald Group Publishing, Yeylaq Marshun, IBM, Addition Financial, Person, Friends, Visual impairment, Buffington, Research to Prevent Blindness, Lens, Park Avenue, Publication, Optometry, VSP, Practice management, Jobson, Humble & Fred, Anita Borg Institute Women of Vision Awards, News, Safety, Fashion design, Management

CHICAGO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, announced today that the 2024 Person of Vision Award will be presented to Ed Buffington, president and CEO of GPN Technologies. The Person of Vision Award Gala will be held on March 14, 2024, at 583 Park Avenue, New York City, in conjunction with Vision Expo East. Prevent Blindness will also be giving special recognition to 20/20 Magazine in celebration of its 50th Anniversary of publication. All proceeds from the event support the sight-saving mission of Prevent Blindness.

Key Points: 
  • Annual Prevent Blindness Person of Vision Award Gala at Vision Expo East to Honor Ed Buffington, GPN Technologies, and Recognize 20/20 Magazine for 50 Years of Publication
    CHICAGO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading eye health and safety nonprofit organization, announced today that the 2024 Person of Vision Award will be presented to Ed Buffington, president and CEO of GPN Technologies .
  • "We are proud to recognize Ed Buffington and 20/20 Magazine at the 2024 Person of Vision Award gala," said Jeff Todd, pres.
  • The Prevent Blindness Person of Vision Award recognizes an individual, corporation and/or organization whose inspired outlook champions healthy vision and its importance for a healthy life.
  • "We are proud to recognize Ed Buffington and 20/20 Magazine at the 2024 Person of Vision Award gala," said Jeff Todd, president and CEO of Prevent Blindness.

Western Midstream Partners, LP Announces Pricing of Notes Offering

Retrieved on: 
Wednesday, September 27, 2023
Oil, Gas, Energy, Partnership, Columbus Circle, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Park Avenue, SMBC Nikko Securities, Sale, Prospectus, Acquisition, WES, Wainwright Securities Inc. v. Wall Street Transcript Corp., NYSE, Broadridge Financial Solutions, Security (finance)

Today, Western Midstream Partners, LP (NYSE: WES) (“WES”) announced that its subsidiary, Western Midstream Operating, LP (“WES Operating”), has priced an offering of $600 million in aggregate principal amount of 6.350% senior notes due 2029 at a price to the public of 99.786% of their face value.

Key Points: 
  • Today, Western Midstream Partners, LP (NYSE: WES) (“WES”) announced that its subsidiary, Western Midstream Operating, LP (“WES Operating”), has priced an offering of $600 million in aggregate principal amount of 6.350% senior notes due 2029 at a price to the public of 99.786% of their face value.
  • The offering of the senior notes is expected to close on September 29, 2023, subject to the satisfaction of customary closing conditions.
  • The senior notes offering is not contingent on the completion of the Meritage Acquisition, and the Meritage Acquisition is not contingent on the completion of this offering.
  • Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and SMBC Nikko Securities America, Inc. are acting as joint book-running managers for the offering.

Faraday Future Announces “At-the-Market” Equity Offering Program

Retrieved on: 
Wednesday, September 27, 2023
EV, Electric Vehicles, Alternative Vehicles, Fuels, Automotive, Automotive Manufacturing, General Automotive, Performance & Special Interest, Vehicle Technology, Manufacturing, Agreement, Attention, Montgomery Street, Stifel, Global Partners, Internet, Telephone, Park Avenue, Sale, Public expenditure, Suite, ATM, Wedbush Securities, Equity capital markets, Prospectus, Agent, Bankruptcy Code, Madison Avenue, Security (finance), Ultimate, Insolvency and Bankruptcy Code, 2016, FF, Share (finance)

Sales of Shares, if any, will be made at or related to then prevailing market prices and, as a result, prices may vary.

Key Points: 
  • Sales of Shares, if any, will be made at or related to then prevailing market prices and, as a result, prices may vary.
  • The volume and timing of sales under the ATM program will be determined at the Company’s discretion.
  • A prospectus supplement related to the offering has been filed with the SEC.
  • Any offer, solicitation or sale will be made only by means of the prospectus supplement and the accompanying prospectus.

Well-Respected New York Plastic Surgery Practice, New You Plastic Surgery, Opens Poughkeepsie, NY, and Englewood, NJ, Practice Locations

Retrieved on: 
Tuesday, September 26, 2023
Insurance, Breast reduction, Rhinoplasty, Multimedia, Suite, Patient, Liberty Street, Breast, Park Avenue, Growth, Injury, Dentistry, Medical device

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- New You Plastic Surgery is a leading provider of cosmetic treatments and plastic surgery procedures, helping individuals enhance their natural beauty and boost their self-confidence. Led by renowned plastic surgeon Dr. Jeremy Nikfarjam, the practice offers a comprehensive range of services, utilizing the latest advancements in technology and techniques to deliver exceptional results. New You Plastic Surgery is thrilled to further expand its reach and impact with the opening of two new state-of-the-art offices in Poughkeepsie and Englewood, offering patients the latest advancements in cosmetic treatments and plastic surgery procedures. Spearheaded by the highly acclaimed plastic surgeon, Dr. Nikfarjam, these new locations aim to provide individuals with the opportunity to enhance their natural beauty and achieve their desired aesthetic goals. Dr. Jeremy Nikfarjam, a visionary in the field of plastic surgery, has dedicated his career to helping patients feel confident and empowered through transformative procedures. With the growth of New You Plastic Surgery, he aims to bring his unparalleled expertise and groundbreaking techniques to a wider audience. At both the Poughkeepsie and Englewood offices, patients can expect a comprehensive range of services tailored to their unique needs. From non-surgical treatments such as Botox and dermal fillers to procedures like breast reduction, facelifts, and liposuction, New You Plastic Surgery offers a wide array of options to help individuals achieve their desired look.

Key Points: 
  • NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- New You Plastic Surgery is a leading provider of cosmetic treatments and plastic surgery procedures, helping individuals enhance their natural beauty and boost their self-confidence.
  • New You Plastic Surgery is thrilled to further expand its reach and impact with the opening of two new state-of-the-art offices in Poughkeepsie and Englewood, offering patients the latest advancements in cosmetic treatments and plastic surgery procedures.
  • Dr. Jeremy Nikfarjam, a visionary in the field of plastic surgery, has dedicated his career to helping patients feel confident and empowered through transformative procedures.
  • More About New You Plastic Surgery:
    New You Plastic Surgery is the practice of board-certified plastic surgeon Dr. Jeremy Nikfarjam.

Terran Orbital Announces Closing of $32.5 Million Public Offering

Retrieved on: 
Monday, September 25, 2023
Technology, Other Defense, Satellite, Aerospace, Software, Manufacturing, Government Technology, Hardware, Robotics, Defense, Maintenance, Park Avenue, Enterprise file synchronization and sharing, Research, Sale, Public expenditure, 3rd Floor, Prospectus, Form, LLAP, Security (finance), NYSE, Orbital Corporation

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering to the Company were approximately $32.5 million, before deducting placement agent’s fees and other offering expenses payable by the Company.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the shelf registration statement.
  • A final prospectus supplement related to the offering was filed with the SEC and may be obtained on the SEC’s website, located at www.sec.gov .

Gorilla Announces $25 Million Registered Direct Offering of Convertible Preferred Stock

Retrieved on: 
Wednesday, September 20, 2023
Attention, Internet of things, Telephone, Park Avenue, Free File, Sale, Prospectus, Equity capital markets, 4th floor, Form, Madison Avenue, Security (finance), GRRR, Gorilla

Each Series A preference share is convertible into ordinary shares of Gorilla at a conversion price of $1.25 per share.

Key Points: 
  • Each Series A preference share is convertible into ordinary shares of Gorilla at a conversion price of $1.25 per share.
  • The closing of the offering is expected to occur on or about September 22, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Gorilla from this offering are expected to be approximately $25 million, before deducting the placement agents’ fees and other offering expenses.
  • Gorilla intends to use the net proceeds from the offering for working capital needs.

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

Retrieved on: 
Tuesday, September 19, 2023
China Biologic Products, IBN, Autoimmunity, ADS, I&I, Park Avenue, Drug Master File, Regulation D, Infection, Research, The Act, Sale, 3rd Floor, Prospectus, Form, Security (finance)

The gross proceeds to the Company from the offering are approximately $1.33 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from the offering are approximately $1.33 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from the offering for general working capital, research and development, and general corporate purposes.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering have been filed with the SEC.

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, September 19, 2023
Park Avenue, Regulation D, RNA, Alport syndrome, Sale, 3rd Floor, Form, Security (finance), Rare, Alport

In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock.

Key Points: 
  • In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock.
  • The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Eloxx from the offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses payable by Eloxx.
  • The offering of the shares of common stock (or common stock equivalents) to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement.

Terran Orbital Announces Pricing of $32.5 Million Public Offering

Retrieved on: 
Tuesday, September 19, 2023
Satellite, Software, Finance, Hardware, Professional Services, Technology, Aerospace, Manufacturing, Maintenance, Park Avenue, Enterprise file synchronization and sharing, Research, Sale, Public expenditure, 3rd Floor, Prospectus, Form, LLAP, Security (finance), NYSE, Orbital Corporation

The offering is expected to close on or about September 21, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about September 21, 2023, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering to the Company are expected to be approximately $32.5 million, before deducting placement agent’s fees and other offering expenses payable by the Company.
  • The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the shelf registration statement.

Terran Orbital Announces Proposed Public Offering

Retrieved on: 
Monday, September 18, 2023
Satellite, Software, Finance, Hardware, Professional Services, Technology, Aerospace, Manufacturing, Maintenance, Park Avenue, Enterprise file synchronization and sharing, Research, Sale, Public expenditure, 3rd Floor, Prospectus, Form, LLAP, Security (finance), NYSE, Orbital Corporation

Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced that it intends to offer and sell in a public offering, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced that it intends to offer and sell in a public offering, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock.
  • All of the shares of common stock (or common stock equivalents) and warrants in the offering are to be offered by the Company.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • Terran Orbital expects to use the net proceeds of the proposed offering for general corporate purposes including capital expenditures, working capital, research and development, and general and administrative expenses, and maintenance of the liquidity covenant in the Company’s debt documents.